Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » First Analysis Upgrades NeoGenomics to Strong Buy After Stock Dips

First Analysis Upgrades NeoGenomics to Strong Buy After Stock Dips

Feb 28, 2020
|
staff reporter

NEW YORK – First Analysis Securities on Thursday upgraded NeoGenomics' shares to Strong Buy from a prior Outperform rating after the firm's shares fell 8 percent following its Q4 earnings report and outlook.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Analysis for the Long Term

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Pricey, But Available

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Pilot Cancer Testing Program for Taiwan

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

PLOS Papers on TB Resistance, Squamous Cell Carcinoma Risk, MicroRNAs in SCC

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.

What's Popular?

In Business News

  1. Spatial Omics Firms Use AGBT as Launchpad for New Tech

    Premium

  2. Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

    Premium

  3. Fulgent Genetics Aims to Use COVID-19 Testing Gains to Grow Clinical Sequencing Business

    Premium

  4. Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

  5. Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.